VBI Vaccines, Inc. - Ordinary Shares (VBIV): Price and Financial Metrics


VBI Vaccines, Inc. - Ordinary Shares (VBIV): $0.85

-0.07 (-7.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VBIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VBIV POWR Grades


  • VBIV scores best on the Sentiment dimension, with a Sentiment rank ahead of 28.86% of US stocks.
  • VBIV's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • VBIV's current lowest rank is in the Quality metric (where it is better than 2.85% of US stocks).

VBIV Stock Summary

  • VBI Vaccines Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.47% of US listed stocks.
  • VBIV's price/sales ratio is 712.15; that's higher than the P/S ratio of 99.36% of US stocks.
  • As for revenue growth, note that VBIV's revenue has grown -40.53% over the past 12 months; that beats the revenue growth of only 4.21% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to VBI Vaccines Inc, a group of peers worth examining would be ONDS, OTRK, ASAN, ESTC, and CDNA.
  • VBIV's SEC filings can be seen here. And to visit VBI Vaccines Inc's official web site, go to www.vbivaccines.com.

VBIV Valuation Summary

  • VBIV's price/sales ratio is 1021.2; this is 8897.36% higher than that of the median Healthcare stock.
  • Over the past 243 months, VBIV's price/sales ratio has gone down 1426.5.
  • Over the past 243 months, VBIV's price/sales ratio has gone down 1426.5.

Below are key valuation metrics over time for VBIV.

Stock Date P/S P/B P/E EV/EBIT
VBIV 2021-08-31 1021.2 5.5 -14.6 -13.8
VBIV 2021-08-30 1004.2 5.4 -14.3 -13.5
VBIV 2021-08-27 1012.7 5.5 -14.4 -13.6
VBIV 2021-08-26 959.0 5.2 -13.7 -12.8
VBIV 2021-08-25 913.7 4.9 -13.0 -12.1
VBIV 2021-08-24 891.0 4.8 -12.7 -11.8

VBIV Growth Metrics

    Its 5 year cash and equivalents growth rate is now at 10.91%.
  • Its 4 year cash and equivalents growth rate is now at 10.91%.
  • Its 5 year net cashflow from operations growth rate is now at -128.65%.
Over the past 15 months, VBIV's revenue has gone down $840,000.

The table below shows VBIV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.631 -39.908 -69.753
2021-09-30 0.714 -37.887 -66.332
2021-06-30 0.905 -48.957 -63.482
2021-03-31 0.947 -46.046 -55.519
2020-12-31 1.061 -47.05 -46.23
2020-09-30 1.471 -39.085 -41.743

VBIV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VBIV has a Quality Grade of F, ranking ahead of 2.02% of graded US stocks.
  • VBIV's asset turnover comes in at 0.004 -- ranking 418th of 681 Pharmaceutical Products stocks.
  • NOVN, CKPT, and ARWR are the stocks whose asset turnover ratios are most correlated with VBIV.

The table below shows VBIV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.004 -9.583 -1.419
2021-03-31 0.005 -8.508 -1.124
2020-12-31 0.006 -7.641 -1.240
2020-09-30 0.010 -5.345 -1.736
2020-06-30 0.014 -4.054 -3.663
2020-03-31 0.019 -3.171 -175.420

VBIV Stock Price Chart Interactive Chart >

Price chart for VBIV

VBIV Price/Volume Stats

Current price $0.85 52-week high $4.31
Prev. close $0.92 52-week low $0.64
Day low $0.84 Volume 1,627,000
Day high $0.96 Avg. volume 2,504,579
50-day MA $1.05 Dividend yield N/A
200-day MA $1.99 Market Cap 219.62M

VBI Vaccines, Inc. - Ordinary Shares (VBIV) Company Bio


VBI Vaccines Inc. develops vaccine candidates and novel technology platforms in Israel and internationally. It develops products based on eVLP, a platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccines platform, a proprietary formulation and process that allows vaccines and biologics to preserve stability, potency, and safety. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.


VBIV Latest News Stream


Event/Time News Detail
Loading, please wait...

VBIV Latest Social Stream


Loading social stream, please wait...

View Full VBIV Social Stream

Latest VBIV News From Around the Web

Below are the latest news stories about VBI Vaccines Inc that investors may wish to consider to help them evaluate VBIV as an investment opportunity.

VBI Vaccines Receives Positive CHMP Opinion for 3-Antigen Hepatitis B Vaccine for Immunization Against Hepatitis B Infection in Adults in the European Union

CAMBRIDGE, Mass., February 25, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion for VBI’s 3-antigen hepatitis B (HBV) vaccine, under the brand name PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)]. The CHMP recommends PreHevbri for active

Yahoo | February 25, 2022

VBI Vaccines Announces PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults

CAMBRIDGE, Mass., February 23, 2022--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that, following discussion at this afternoon’s meeting of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] now joins the list of recommended products for prophylactic adult vaccination ag

Yahoo | February 23, 2022

NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of -7.69% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022

During the last session, VBI Vaccines Inc. (NASDAQ:VBIV)’s traded shares were 1.85 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stock’s price was $1.44, reflecting an intraday loss of -5.88% or -$0.09. The 52-week high for the VBIV share is $4.31, that puts it down … VBI Vaccines Inc. (NASDAQ: VBIV)’s Stock Is Down -60.98% Since The Beginning Of The Year, Likely To Sustain The Trend In 2022 Read More »

Marketing Sentinel | February 18, 2022

What Type Of Shareholders Make Up VBI Vaccines Inc.'s (NASDAQ:VBIV) Share Registry?

The big shareholder groups in VBI Vaccines Inc. ( NASDAQ:VBIV ) have power over the company. Generally speaking, as a...

Yahoo | February 9, 2022

Read More 'VBIV' Stories Here

VBIV Price Returns

1-mo -7.22%
3-mo -48.80%
6-mo -64.58%
1-year -78.80%
3-year -27.35%
5-year -79.86%
YTD -63.68%
2021 -14.91%
2020 99.28%
2019 -13.75%
2018 -62.53%
2017 37.74%

Continue Researching VBIV

Here are a few links from around the web to help you further your research on VBI Vaccines Inc's stock as an investment opportunity:

VBI Vaccines Inc (VBIV) Stock Price | Nasdaq
VBI Vaccines Inc (VBIV) Stock Quote, History and News - Yahoo Finance
VBI Vaccines Inc (VBIV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5307 seconds.